Anavex Life Sciences Corp

NASDAQ AVXL

Data sourced from

and

Download Data

Anavex Life Sciences Corp Average Collection Period 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 20, 2024

Anavex Life Sciences Corp Average Collection Period 1 year YoY Change (%) is NA for the Trailing 12 Months (TTM) ending September 20, 2024. The average collection period measures the average number of days it takes for a company to collect payments from its customers. It is calculated by dividing 365 by the ratio of revenue to the average of receivables and other current assets. A lower average collection period indicates a more efficient collection process and better cash flow management, while a higher period may suggest delayed payments and potential liquidity challenges. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

NASDAQ: AVXL

Anavex Life Sciences Corp

CEO	Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
IPO Date	Aug. 2, 2006
Location	United States
Headquarters	630 5th Avenue, New York, NY, United States, 10111
Employees	40
Sector	Healthcare
Industry	Biotechnology

Description

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Key trends